Have a feature idea you'd love to see implemented?
Let us know!
PLRX Pliant Therapeutics Inc
Price (delayed)
$12.85
Market cap
$781.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.34
Enterprise value
$761.08M
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual
Highlights
PLRX's gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
Key stats
What are the main financial stats of PLRX
Market
Valuations
Earnings
Shares outstanding
60.85M
Market cap
$781.97M
Enterprise value
$761.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$199.17M
EBITDA
-$193.84M
Free cash flow
-$136.64M
Per share
Balance sheet
Liquidity
EPS
-$3.34
Free cash flow per share
-$2.25
Book value per share
$5.69
Revenue per share
$0
TBVPS
$7.34
Total assets
$445.67M
Total liabilities
$99.84M
Debt
$60.21M
Equity
$345.82M
Working capital
$370.08M
Debt to equity
0.17
Current ratio
10.26
Quick ratio
10.16
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-41.1%
Return on equity
-48.9%
Return on invested capital
-47.5%
Return on capital employed
-49.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLRX stock price
How has the Pliant Therapeutics stock price performed over time
Intraday
0.94%
1 week
0%
1 month
-12.35%
1 year
-9.12%
YTD
-29.04%
QTD
14.63%
Financial performance
How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$222.08M
Net income
-$201.68M
Gross margin
N/A
Net margin
N/A
PLRX's gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
The net income has contracted by 30% YoY and by 9% from the previous quarter
PLRX's operating income is down by 27% year-on-year and by 7% since the previous quarter
Growth
What is Pliant Therapeutics's growth rate over time
Valuation
What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
2.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 20% year-on-year and by 8% since the previous quarter
The equity has contracted by 31% YoY and by 12% from the previous quarter
PLRX's price to book (P/B) is 16% lower than its 5-year quarterly average of 2.7 but 13% higher than its last 4 quarters average of 2.0
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Pliant Therapeutics business performance
The ROE has dropped by 50% year-on-year and by 19% since the previous quarter
Pliant Therapeutics's return on assets has decreased by 37% YoY and by 14% QoQ
The company's return on invested capital fell by 36% YoY and by 14% QoQ
Dividends
What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLRX.
Financial health
How did Pliant Therapeutics financials performed over time
The total liabilities has soared by 167% YoY and by 10% from the previous quarter
The company's quick ratio fell by 47% YoY and by 28% QoQ
Pliant Therapeutics's debt is 83% lower than its equity
The equity has contracted by 31% YoY and by 12% from the previous quarter
PLRX's debt to equity is up by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.